EU MDCG 2026-6: Clinical Evidence Guidance for Orphan IVDs

The European Commission published MDCG 2026-6, Guidance on clinical evidence for orphan IVDs on 3 November 2026. The 32-page guidance explains how manufacturers can justify clinical evidence for orphan in vitro diagnostic medical devices under the EU IVDR. MDCG is the Medical Device Coordination Group; IVDR is the EU In Vitro Diagnostic Medical Devices Regulation.

This is final, legally non-binding MDCG guidance. It does not amend the IVDR, create a separate marketing authorization, or waive the applicable General Safety and Performance Requirements (GSPRs). Its practical contribution is a common approach to orphan status, justified limitations in pre-market clinical performance data, post-market evidence generation, and expert-panel advice.

Which IVDs can qualify?

Section 4.1 sets two cumulative tests. The IVD must be intended to test for a disease, condition, or circumstance presenting in not more than 12,000 individuals in the EU per year. There must also be either insufficient available alternatives or an expected clinical benefit compared with available alternatives or the state of the art.

The threshold concerns epidemiology, rather than the number of tests sold or performed. Screening may test more people than ultimately have the condition, and a patient may require repeated testing. Manufacturers should document their population estimates and scientific rationale in the material submitted to the notified body or expert panel.

Section 4.2.1 also addresses medically justified orphan subpopulations within a more common condition. Arbitrarily narrowing an intended population to meet the threshold is not acceptable. For rare diseases affecting no more than 5 in 10,000 people in the EU, the guidance accepts the specified epidemiological justification where the IVD is expected to identify, diagnose, or provide management information for not more than 12,000 affected individuals annually.

Two boundaries matter for product planning:

• For a device with both orphan and non-orphan indications, section 4.3 applies the orphan evidence considerations only to the orphan indications.
• CE-marked orphan IVD status provides no market exclusivity. Other devices may qualify for the same disease, condition, or circumstance.

Limited pre-market data still need a defensible evidence package

Section 5 explains that limitations in clinical performance data can be acceptable when all of the following are justified:

1. All available data have been evaluated, and the clinical performance limitations have been identified.
2. The existing evidence demonstrates conformity with the relevant GSPRs, an acceptable benefit-risk ratio, and an expected clinical benefit, considering the state of the art and patient safety.
3. Generating further clinical performance data in an acceptable pre-market timeframe is infeasible or disproportionate.
4. Adequate post-market performance follow-up (PMPF) and post-market surveillance (PMS) plans will address the remaining limitations in a timely manner, as far as possible.
5. Users will receive adequate information about orphan status, pre-market data limitations, and reporting incidents, complaints, and other clinical experience.

The fifth point can be addressed through labelling, instructions for use, the summary of safety and performance for Class C and D IVDs, and/or accompanying documentation. Footnote 8 acknowledges that residual limitations can remain acceptable for some orphan IVDs if appropriately justified; the guidance does not promise that every uncertainty can be eliminated after launch.

Sections 6–8 discuss non-clinical evidence and clinical performance data generation. They do not create a blanket exemption from clinical evidence. Annex 3 provides a case-specific framework for extrapolating clinical performance data from a non-orphan population: partial extrapolation combines evidence sources, while full extrapolation is less common and requires sufficient justification. The manufacturer must justify the approach, and the notified body assesses it where applicable.

Certificates can carry specific post-market conditions

Sections 10.1–10.3 connect the performance evaluation report (PER) to conformity assessment and surveillance. Where the evidence is sufficient but needs further completion or confirmation, a notified body may issue a certificate with specific conditions or provisions under IVDR Article 51(3) and Annex VII, section 4.8.

Conditions may require defined PMS or PMPF activities within a specified period. They bind the manufacturer, and the notified body monitors compliance during surveillance. Failure to meet them requires evaluation of the certificate implications and can lead to suspension or withdrawal. Orphan status alone therefore does not establish entitlement to certification.

Expert-panel advice: the scope and timing matter

Section 11 describes voluntary expert-panel consultation managed through the European Medicines Agency (EMA). It covers the following situations:

Under section 11.2, the panel will endeavour to provide status-only advice within 60 days. For advice on both orphan status and clinical performance data, it will endeavour to respond within 90 days, provided the advice is simple. It can also provide the two parts separately. These are qualified advice targets, rather than guaranteed certification deadlines.

The voluntary consultation is separate from the performance evaluation consultation procedure (PECP). Under section 11.3, PECP could apply to a Class D orphan IVD under IVDR Article 48(6). Where it does, the notified body must account for the requirement to provide the PER to the IVD expert panel within five days of receipt from the manufacturer. Neither orphan status nor voluntary advice removes applicable PECP obligations.

In-house IVDs have a different regulatory boundary

Section 3 makes the general principles in sections 4–9 and Annexes 3–4 relevant to orphan IVDs manufactured and used within EU health institutions under IVDR Article 5(5). Such devices must meet the relevant GSPRs, and their orphan claims need documentation.

The guidance expressly excludes its statements about notified bodies, certification, CE marking, reports, and expert panels from that in-house context. Health institutions should read it alongside MDCG 2023-1 and question 9 of MDCG 2025-5; they should not infer that the commercial certification or voluntary consultation arrangements automatically apply to in-house devices.

How to use the guidance in an evidence plan

Pure Global analysis: Build the assessment around the individual indication. First document the epidemiological case and the alternative-device or clinical-benefit justification. Then connect each remaining evidence gap to its pre-market justification, the proposed post-market activity, and the information users will receive.

Annex 2 offers a useful PER review aid, while Annexes 3 and 4 help test extrapolation and study-design choices. For a product with mixed indications, keep the orphan justification distinct from the evidence supporting non-orphan claims. Discuss any proposed certificate conditions with the notified body and check EMA's current consultation arrangements before planning an advice request. This approach turns the guidance into a reviewable evidence strategy without assuming that orphan status guarantees acceptance of a particular data package.